Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide

Journal of Clinical Pharmacology

Volumn 52, Issue 5, 2012, Pages 645-655

  Yan, Jing He ^a   Jarugula, Venkateswar ^a   Sabo, Ron ^b   Papst, Cheraz Cherif ^b   Zhang, Jack ^b   Dole, William P ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

aliskiren; bioequivalence; hydrochlorothiazide; plasma renin activity; single pill combination

Indexed keywords

ALISKIREN; HYDROCHLOROTHIAZIDE;

ADULT; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PILL; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC HYPERTENSION; TABLET;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMIDES; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; DIURETICS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RENIN; TABLETS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860282071     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011405499     Document Type: Article

References (43)

1. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009 ; 27: 2121-2158
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 ; 42: 1206-1252 (Pubitemid 37553153)
3. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004 ; 363: 2049-2051 (Pubitemid 38781107)
4. Jamerson K, Bakris GL, Dahlöf B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007 ; 16: 80-86 (Pubitemid 47050368)
5. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 ; 359: 2417-2428
6. Skolnik MS, Beck JD, Clark M. Combination antihypertensive drugs: recommendations for use. Am Fam Physician. 2000 ; 61: 3049-3056 (Pubitemid 30347016)
7. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther. 2003 ; 1: 43-50
8. Lijnen P, Fagard R, Staessen J, Amery A. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol. 1981 ; 12: 387-392 (Pubitemid 11039910)
9. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 ; 345: 861-869
10. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 ; 345: 851-860
11. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 ; 345: 870-878
12. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs. 2007 ; 67: 1767-1792 (Pubitemid 47263181)
13. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens. 2006 ; 24: 243-256 (Pubitemid 43348229)
14. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002 ; 39: E1 - E8
15. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 ; 25: 217-226 (Pubitemid 44885684)
16. Black HR, Kribben A, Palacios Aguirre F, et al. Aliskiren as monotherapy or in combination with hydrochlorothiazide provides effective BP lowering in patients with systolic BP 160-<180 mmHg (ACQUIRE study). J Clin Hypertens. 2010 ; 12:
17. Basile J, Babazadeh S, Lillestol M, et al. First-line aliskiren/hydrochlorothiazide combination treatment lowers BP more effectively than hydrochlorothiazide alone in older patients with stage 2 hypertension (ACTION study). J Clin Hypertens. 2010 ; 12:
18. Nickenig G, Simanenkov V, Lembo G, et al. Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Press. 2008 ; 17: 31-40
19. Blumenstein M, Romaszko J, Calderon A, et al. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin. 2009 ; 25: 903-910
20. Sica D, Gradman AH, Lederballe O, et al. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J. 2006 ; 27:
21. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008 ; 26: 589-599
22. Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005 ; 27: 578-587 (Pubitemid 40835968)
23. Vaidyanathan S, Warren V, Yeh C, Bizot MN, Dieterich HA, Dole WP. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol. 2007 ; 47: 192-200 (Pubitemid 46146485)
24. Limoges D, Dieterich HA, Yeh CM, Vaidyanathan S, Howard D, Dole WP. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther. 2008 ; 46: 252-258 (Pubitemid 351663162)
25. Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract. 2006 ; 60: 1343-1356 (Pubitemid 44560330)
26. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007 ; 49: 1157-1163 (Pubitemid 46400330)
27. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension. 2007 ; 49: 1047-1055 (Pubitemid 351664315)
28. Philipp T, Schmieder RE, Guerediaga J, et al. Aliskiren-based therapy provides long-term renin system suppression in patients with hypertension in a 52-wk comparator trial with hydrochlorothiazide-based therapy. J Clin Hypertens. 2007 ; 9:
29. Gradman AH, Flack JM, Arora V, et al. Suppression of the renin system by the novel orally effective direct renin inhibitor aliskiren: a pooled analysis of 1612 patients with hypertension. Circulation. 2006 ; 114: 773
30. Drummond W, Munger MA, Rafique M, Maboudian M, Khan M, Keefe D. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens. 2007 ; 9: 742-750
31. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007 ; 370: 221-229 (Pubitemid 47069535)
32. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007 ; 8: 190-198 (Pubitemid 351166266)
33. Blumenfeld JD, Sealey JE, Alderman MH, et al. Plasma renin activity in the emergency department and its independent association with acute myocardial infarction. Am J Hypertens. 2000 ; 13: 855-863 (Pubitemid 30628221)
34. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997 ; 10: 1-8 (Pubitemid 27038966)
35. Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004 ; 25: 292-299 (Pubitemid 38295437)
36. Vergaro G, Fontana M, Poletti R, et al. Plasma renin activity is an independent prognostic factor in chronic heart failure [abstract 2493]. Eur Heart J. 2008 ; 29: 393
37. Muhlestein JB, May HT, Bair TL, et al. Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol. 2010 ; 106: 764-769
38. Rouleau JL, Packer M, Moyé L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994 ; 24: 583-591 (Pubitemid 24295729)
39. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009 ; 24: 1663-1671
40. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007 ; 25: 1105-1187 (Pubitemid 46924065)
41. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007 ; 120: 713-719 (Pubitemid 47176510)
42. Abd-Allah NM, Hassan FH, Esmat AY, Hammad SA. Age dependence of the levels of plasma norepinephrine, aldosterone, renin activity and urinary vanillylmandelic acid in normal and essential hypertensives. Biol Res. 2004 ; 37: 95-106 (Pubitemid 38786646)
43. Anderson GH. Effect of age on hypertension: analysis of over 4,800 referred hypertensive patients. Saudi J Kidney Dis Transpl. 1999 ; 10: 286-297